[go: up one dir, main page]

DE69507956D1 - Zyklische keton peroxyde zubereitungen - Google Patents

Zyklische keton peroxyde zubereitungen

Info

Publication number
DE69507956D1
DE69507956D1 DE69507956T DE69507956T DE69507956D1 DE 69507956 D1 DE69507956 D1 DE 69507956D1 DE 69507956 T DE69507956 T DE 69507956T DE 69507956 T DE69507956 T DE 69507956T DE 69507956 D1 DE69507956 D1 DE 69507956D1
Authority
DE
Germany
Prior art keywords
cyclic ketone
pct
ketone peroxide
peroxyde
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69507956T
Other languages
English (en)
Other versions
DE69507956T2 (de
Inventor
Reinder Torenbeek
John Meijer
Andreas Hogt
Gerrit Bekendam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8217055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69507956(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE69507956D1 publication Critical patent/DE69507956D1/de
Publication of DE69507956T2 publication Critical patent/DE69507956T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/92—Measuring, controlling or regulating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F4/00—Polymerisation catalysts
    • C08F4/28—Oxygen or compounds releasing free oxygen
    • C08F4/32—Organic compounds
    • C08F4/38—Mixtures of peroxy-compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/50—Partial depolymerisation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/14—Peroxides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C2948/00—Indexing scheme relating to extrusion moulding
    • B29C2948/92—Measuring, controlling or regulating
    • B29C2948/92504—Controlled parameter
    • B29C2948/92704—Temperature
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/022—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2810/00—Chemical modification of a polymer
    • C08F2810/10—Chemical modification of a polymer including a reactive processing step which leads, inter alia, to morphological and/or rheological modifications, e.g. visbreaking

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Mechanical Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polymerization Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
DE69507956T 1994-07-21 1995-07-14 Zyklische keton peroxyde zubereitungen Expired - Fee Related DE69507956T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202136 1994-07-21
PCT/EP1995/002830 WO1996003397A1 (en) 1994-07-21 1995-07-14 Cyclic ketone peroxide formulations

Publications (2)

Publication Number Publication Date
DE69507956D1 true DE69507956D1 (de) 1999-04-01
DE69507956T2 DE69507956T2 (de) 1999-09-09

Family

ID=8217055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69507956T Expired - Fee Related DE69507956T2 (de) 1994-07-21 1995-07-14 Zyklische keton peroxyde zubereitungen

Country Status (17)

Country Link
US (1) US5808110A (de)
EP (1) EP0772609B1 (de)
JP (1) JP3794701B2 (de)
KR (1) KR100441557B1 (de)
CN (1) CN1068323C (de)
AT (1) ATE176910T1 (de)
AU (1) AU686466B2 (de)
BR (1) BR9508409A (de)
CA (1) CA2195537C (de)
CZ (1) CZ18497A3 (de)
DE (1) DE69507956T2 (de)
HU (1) HU216142B (de)
MX (1) MX9700535A (de)
PL (1) PL179659B1 (de)
RU (1) RU2154649C2 (de)
TW (1) TW414709B (de)
WO (1) WO1996003397A1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR001122A1 (es) * 1995-03-06 1997-09-24 Akzo Nobel Nv Procedimiento de polímerizacion que utiliza una composición de peróxidos (co)polímero funcionalizadoobtenido por el proceso y uso de una composición de peróxidos
JP3991439B2 (ja) * 1997-08-04 2007-10-17 東レ株式会社 繊維強化プラスチックおよび繊維強化プラスチックの成形方法
CA2315683A1 (en) * 1997-12-22 1999-07-01 Akzo Nobel Nv Ignition improved fuels
GB9809108D0 (en) * 1998-04-30 1998-07-01 British Nuclear Fuels Plc Dimer
TR200101809T2 (tr) * 1998-10-16 2002-01-21 Akzo Nobel N.V. Halkalı keton peroksitler için iyileştirilmiş pasifleştirme(flegmatizasyon)
WO2001068723A2 (de) * 2000-03-16 2001-09-20 Basell Polyolefine Gmbh Verfahren zur herstellung von polyethylen
KR100819680B1 (ko) 2000-08-15 2008-04-04 아크조 노벨 엔.브이. 트리옥세판 화합물
EP1186618A1 (de) * 2000-09-08 2002-03-13 ATOFINA Research Heterophasische Propylenpolymere mit kontrollierten rheologischen Werten
EP1216991A1 (de) * 2000-12-22 2002-06-26 Akzo Nobel N.V. Transportable reaktive Phlegmatisierungsmittel enthaltende organische Peroxidzusammensetzungen und ihre sichere Verpackung
CN1296353C (zh) * 2000-12-29 2007-01-24 阿克佐诺贝尔股份有限公司 甲基·丙基酮过氧化物制剂及其在固化不饱和聚酯树脂的方法中的用途
EP1219602A1 (de) * 2000-12-29 2002-07-03 Akzo Nobel N.V. Methylisopropylketonperoxidformulierungen und ihre Verwendung zur Härtung ungesättigter Polyester
US6762208B2 (en) 2001-10-01 2004-07-13 Air Products And Chemicals, Inc. Alkane diol foam controlling agents
EP1312617A1 (de) 2001-11-14 2003-05-21 ATOFINA Research Schlagzähes Polypropen
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP5069843B2 (ja) 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
DK2364996T3 (en) 2002-09-27 2017-02-06 Xencor Inc Optimized Fc variants and methods for their formation
US7252784B2 (en) 2002-12-06 2007-08-07 Akzo Nobel N.V. Cyclic ketone peroxide formulations
ATE409696T1 (de) * 2002-12-06 2008-10-15 Akzo Nobel Nv Formulierungen cylischer ketonperoxide
EP1447404A1 (de) * 2003-02-13 2004-08-18 Akzo Nobel N.V. Verbesserte Zyclische Keton Peroxyde Zusammenstellungen
WO2004072059A1 (en) * 2003-02-13 2004-08-26 Akzo Nobel N.V. Storage stable cyclic ketone peroxide compositions
EP2478912B1 (de) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung
RU2404810C9 (ru) 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
DE102004029732A1 (de) 2004-06-21 2006-01-19 Basf Ag Hilfsmittel enthaltend Cyclohexanpolycarbonsäurederivate
CN101014619B (zh) 2004-07-15 2010-11-03 赞科股份有限公司 优化的Fc变体
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
WO2007099056A1 (en) 2006-03-03 2007-09-07 Akzo Nobel N.V. Process for the modification of biodegradable polymers
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2662236A1 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DE102009002652A1 (de) * 2009-04-27 2010-10-28 BAM Bundesanstalt für Materialforschung und -prüfung Triacetontriperoxid und Diacetondiperoxid-Derivat, Verfahren zu ihrer Herstellung sowie ihre Verwendung
SG177324A1 (en) * 2009-06-23 2012-02-28 Dow Global Technologies Llc Controlled-rheology polypropylene
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
CA2781578A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
CN102869359A (zh) 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法
CN102971340A (zh) 2010-03-29 2013-03-13 酵活有限公司 具有增强的或抑制的效应子功能的抗体
RU2012148699A (ru) 2010-04-16 2014-05-27 Дженентек, Инк. Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
EP2637692A4 (de) 2010-11-12 2014-09-10 Scott & White Healthcare Antikörper gegen den endothelialen tumormarker 8
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
FR2971510B1 (fr) * 2011-02-10 2013-03-22 Arkema France Polymerisation radicalaire de l'ethylene amorcee par des peroxydes organiques a haute productivite
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2742067A4 (de) 2011-08-12 2015-03-04 Omeros Corp Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung
MX2014001595A (es) 2011-08-12 2014-04-14 Hoffmann La Roche Compuestos de imidazol, composiciones y metodos de uso.
WO2013041539A1 (en) 2011-09-20 2013-03-28 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
CN102584782A (zh) * 2011-12-31 2012-07-18 北京理工大学 过氧化丙酮四聚体的制备方法
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CA2881480A1 (en) * 2012-08-17 2014-02-20 Akzo Nobel Chemicals International B.V. Process for curing thermoset resins
AU2013304065B2 (en) * 2012-08-17 2016-06-16 Akzo Nobel Chemicals International B.V. Process for curing thermoset resins
DE102013112821A1 (de) 2012-11-30 2014-06-05 Shell Internationale Research Maatschappij B.V. Kraftstoffzusammensetzungen
ES2709724T3 (es) * 2012-12-05 2019-04-17 Akzo Nobel Chemicals Int Bv Mezcla madre de peróxido basada en biorresina
SG11201503897XA (en) * 2012-12-05 2015-06-29 Akzo Nobel Chemicals Int Bv Peroxide masterbatch based on bioresin
CN104822752B (zh) * 2012-12-05 2017-04-19 阿克佐诺贝尔化学国际公司 包含环酮过氧化物的母体混合物
TR201900036T4 (tr) * 2012-12-05 2019-02-21 Akzo Nobel Chemicals Int Bv Bir siklik keton peroksit içeren ana karışım.
AR093663A1 (es) * 2012-12-05 2015-06-17 Akzo Nobel Chemicals Int Bv Lote maestro de peroxido basado en bioresina
AR093664A1 (es) * 2012-12-05 2015-06-17 Akzo Nobel Chemicals Int Bv Mezcla madre formada por un peroxido de cetona ciclico
EP2935533B1 (de) 2012-12-21 2019-03-27 Shell International Research Maatschappij B.V. Verwendung einer organischen sonnenschutzmittelkomponente in einer dieselkraftstoffzusammensetzung
RU2016112568A (ru) 2013-09-05 2017-10-06 Дженентек, Инк. Антипролиферативные соединения
AR097894A1 (es) 2013-10-03 2016-04-20 Hoffmann La Roche Inhibidores terapéuticos de cdk8 o uso de los mismos
EP3060633A1 (de) 2013-10-24 2016-08-31 Shell Internationale Research Maatschappij B.V. Flüssigkraftstoffzusammensetzungen
EP3083905A1 (de) 2013-12-16 2016-10-26 Shell Internationale Research Maatschappij B.V. Flüssigkraftstoffzusammensetzungen
SG11201604956SA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
WO2015135865A1 (en) * 2014-03-11 2015-09-17 Akzo Nobel Chemicals International B.V. Cyclic ketone peroxide composition
DK3126394T3 (da) 2014-03-31 2020-01-13 Hoffmann La Roche Anti-OX40-antistoffer og fremgangsmåder til anvendelse
SG11201608106PA (en) 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
EP2949732B1 (de) 2014-05-28 2018-06-20 Shell International Research Maatschappij B.V. Verwendung einer oxanilid-verbindung in einer dieselkraftstoffzusammensetzung für den zweck der modifizierung der zündverzögerung und/oder der brenndauer
FR3022251A1 (fr) 2014-06-13 2015-12-18 Arkema France Solvant organique pour peroxydes
WO2016036873A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016044694A1 (en) 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
EP3204379B1 (de) 2014-10-10 2019-03-06 Genentech, Inc. Pyrrolidinamid-verbindungen als histondemethylase-inhibitoren
AU2015343337A1 (en) 2014-11-03 2017-06-15 Genentech, Inc. Assays for detecting T cell immune subsets and methods of use thereof
MX2017005929A (es) 2014-11-06 2017-11-20 Genentech Inc Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
WO2016077375A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016106340A2 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
CN107208138A (zh) 2014-12-30 2017-09-26 豪夫迈·罗氏有限公司 用于癌症预后和治疗的方法和组合物
EP3242872B1 (de) 2015-01-09 2019-07-03 Genentech, Inc. (piperidin-3-yl)(naphthalen-2-yl)methanon-derivate und verwandte verbindungen als inhibitoren der histon demethylase kdm2b zur behandlung von krebs
EP3242875B1 (de) 2015-01-09 2022-02-23 Genentech, Inc. 4,5-dihydroimidazol- derivate und ihre verwendung als histone demethylase (kdm2b) inhibitoren
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック， インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
EP3250552B1 (de) 2015-01-30 2019-03-27 Genentech, Inc. Therapeutische verbindungen und verwendungen davon
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
ES2789500T5 (es) 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
CN107810011A (zh) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 使用抗ox40抗体治疗癌症的方法
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
US10208056B2 (en) 2015-08-26 2019-02-19 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
WO2017081199A1 (en) 2015-11-11 2017-05-18 Shell Internationale Research Maatschappij B.V. Process for preparing a diesel fuel composition
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
AU2017225854B2 (en) 2016-02-29 2020-11-19 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3443120A2 (de) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Verfahren zur überwachung und behandlung von krebs
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
EP3464270B1 (de) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclische inhibitoren von cbp/ep300 und deren verwendung bei der behandlung von krebs
CN109476663B (zh) 2016-05-24 2021-11-09 基因泰克公司 用于治疗癌症的吡唑并吡啶衍生物
EP3469099A1 (de) 2016-06-08 2019-04-17 F. Hoffmann-La Roche AG Diagnose- und therapieverfahren für krebs
PT3468997T (pt) 2016-06-08 2023-12-07 Debra Zack Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
CN110418851A (zh) 2016-10-06 2019-11-05 基因泰克公司 癌症的治疗和诊断方法
WO2018077976A1 (en) 2016-10-27 2018-05-03 Shell Internationale Research Maatschappij B.V. Process for preparing an automotive gasoil
US11555076B2 (en) 2016-10-29 2023-01-17 Genentech, Inc. Anti-MIC antibodies and methods of use
FR3060011B1 (fr) * 2016-12-08 2020-06-26 Arkema France Agent de durcissement pour durcir une resine de polymere
WO2018206729A1 (en) 2017-05-11 2018-11-15 Shell Internationale Research Maatschappij B.V. Process for preparing an automotive gas oil fraction
CA3069469A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US11369608B2 (en) 2017-10-27 2022-06-28 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting AVIL expression
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11332620B2 (en) * 2018-03-13 2022-05-17 Nouryon Chemicals International B.V. Solution comprising a dye
CN108503885A (zh) * 2018-05-28 2018-09-07 广州印田新材料有限公司 一种含有酯类减敏剂的稳定的环酮过氧化物组合物
CN108586802A (zh) * 2018-05-28 2018-09-28 广州印田新材料有限公司 含有酯类减敏剂的稳定环酮过氧化物组合物的制备方法
KR20210024550A (ko) 2018-06-23 2021-03-05 제넨테크, 인크. Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
US11499107B2 (en) 2018-07-02 2022-11-15 Shell Usa, Inc. Liquid fuel compositions
CN112839644A (zh) 2018-07-18 2021-05-25 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
WO2020051099A1 (en) 2018-09-03 2020-03-12 Genentech, Inc. Carboxamide and sulfonamide derivatives useful as tead modulators
MX2021003214A (es) 2018-09-19 2021-05-12 Genentech Inc Metodos terapeuticos y de diagnostico para el cancer de vejiga.
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
JP2022512744A (ja) 2018-10-18 2022-02-07 ジェネンテック， インコーポレイテッド 肉腫様腎臓がんのための診断および治療方法
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
MX2021010313A (es) 2019-02-27 2021-09-23 Genentech Inc Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
CA3133821A1 (en) 2019-05-03 2020-11-12 Genentech, Inc. Methods of treating cancer with an anti-pd-l1 antibody
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP4025608A1 (de) 2019-09-04 2022-07-13 F. Hoffmann-La Roche AG Cd8-bindende mittel und verwendungen davon
EP4034532A1 (de) 2019-09-26 2022-08-03 Exelixis, Inc. Pyridonverbindungen und verfahren zur verwendung bei der modulation einer proteinkinase
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
FR3101349B1 (fr) * 2019-09-27 2022-02-25 Arkema France Composition anhydre solide sous forme de poudre comprenant au moins un peroxyde organique, au moins un agent flegmatisant et au moins un liant et procédé préparation correspondant
WO2021083949A1 (en) 2019-10-29 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds for the treatment of cancer
WO2021092171A1 (en) 2019-11-06 2021-05-14 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
EP4058435A1 (de) 2019-11-13 2022-09-21 Genentech, Inc. Therapeutische verbindungen und verfahren zur verwendung
CN117417448A (zh) 2019-12-13 2024-01-19 基因泰克公司 抗ly6g6d抗体及使用方法
JP2023511595A (ja) 2020-01-27 2023-03-20 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔアンタゴニスト抗体を用いたがんを処置するための方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
JP2023520515A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド がんに対する治療方法及び診断方法
EP4143345A1 (de) 2020-04-28 2023-03-08 Genentech, Inc. Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
EP4168118A1 (de) 2020-06-18 2023-04-26 Genentech, Inc. Behandlung mit anti-tigit-antikörpern und pd-1-achsen-bindenden antagonisten
EP4172621A1 (de) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des risikos des wiederauftretens und/oder tods von patienten mit solidem krebs nach präoperativen adjuvanten therapien
JP2023531290A (ja) 2020-06-30 2023-07-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20230094198A (ko) 2020-09-23 2023-06-27 에라스카, 아이엔씨. 3환식 피리돈 및 피리미돈
KR20230082632A (ko) 2020-10-05 2023-06-08 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CA3211063A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
KR20240026948A (ko) 2021-05-25 2024-02-29 에라스카, 아이엔씨. 황 함유 헤테로방향족 트리사이클릭 kras 억제제
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
TW202321261A (zh) 2021-08-10 2023-06-01 美商伊瑞斯卡公司 選擇性ｋｒａｓ抑制劑
WO2023097195A1 (en) 2021-11-24 2023-06-01 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
EP4504780A1 (de) 2022-04-01 2025-02-12 Genentech, Inc. Dosierung zur behandlung mit bispezifischen anti-fcrh5/anti-cd3-antikörpern
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
IL318216A (en) 2022-07-13 2025-03-01 Genentech Inc Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
KR20250038674A (ko) 2022-08-11 2025-03-19 에프. 호프만-라 로슈 아게 바이시클릭 테트라히드로티아제핀 유도체
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
AR130169A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados de tetrahidrotiazepina bicíclicos
AU2023322638A1 (en) 2022-08-11 2024-11-28 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
WO2025049277A1 (en) 2023-08-25 2025-03-06 Genentech, Inc. Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB827511A (en) * 1957-02-07 1960-02-03 Laporte Chemical Improvements in or relating to methyl ethyl ketone peroxides
US3003000A (en) * 1959-07-01 1961-10-03 Research Corp Organic peroxides
GB912061A (en) * 1959-09-01 1962-12-05 Laporte Chemical Improvements in or relating to the manufacture of ketone peroxides
GB1072728A (en) * 1965-11-17 1967-06-21 Wallace & Tiernan Inc Stabilised ketone peroxide compositions
US3649546A (en) * 1967-05-15 1972-03-14 Norac Co Non-hazardous ketone peroxide polymerization initiators
US3867461A (en) * 1968-02-05 1975-02-18 Argus Chem Non-hazardous ketone peroxide compositions
AT319589B (de) * 1972-07-25 1974-12-27 Chemie Linz Ag Verfahren zur Herstellung von Polypropylen
TR17756A (tr) * 1972-07-25 1976-07-01 Oesterr Stickstoffwerke Ag Mahdut molekuel agirligi dagilisina sahip polipropilenin imal edilmesine mahsus usul
US4271279A (en) * 1975-06-30 1981-06-02 Argus Chemical Corporation Cyclic perketals and their use for cross-linking high density polyethylene
DE2600656C2 (de) * 1975-06-30 1985-03-21 Argus Chemical Corp., New York, N.Y. Cyclische Peroxide
IT1104579B (it) * 1978-12-29 1985-10-21 Montedison Spa Procedimento per la preparazione di miscele ferossidiche
NL8502042A (nl) * 1985-07-16 1985-10-01 Akzo Nv Nieuwe geflegmatiseerde keton peroxide samenstellingen en hun toepassing bij de vervaardiging van gietkernen of -vormen.
US4956416A (en) * 1988-08-18 1990-09-11 Atochem North America, Inc. Amino or hydrazino peroxides, derivatives and their uses

Also Published As

Publication number Publication date
AU686466B2 (en) 1998-02-05
MX9700535A (es) 1997-04-30
US5808110A (en) 1998-09-15
BR9508409A (pt) 1997-12-23
RU2154649C2 (ru) 2000-08-20
HU216142B (hu) 1999-04-28
DE69507956T2 (de) 1999-09-09
EP0772609A1 (de) 1997-05-14
JP3794701B2 (ja) 2006-07-12
PL318322A1 (en) 1997-06-09
KR970704727A (ko) 1997-09-06
CA2195537C (en) 2006-09-12
PL179659B1 (pl) 2000-10-31
AU3643795A (en) 1996-02-22
TW414709B (en) 2000-12-11
KR100441557B1 (ko) 2005-08-05
ATE176910T1 (de) 1999-03-15
CN1153514A (zh) 1997-07-02
WO1996003397A1 (en) 1996-02-08
HUT77800A (hu) 1998-08-28
CZ18497A3 (en) 1997-07-16
JPH10503229A (ja) 1998-03-24
CN1068323C (zh) 2001-07-11
EP0772609B1 (de) 1999-02-24
CA2195537A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
DE69507956D1 (de) Zyklische keton peroxyde zubereitungen
ATE169317T1 (de) Pyridobismidazole enthaltendes rigid-rod-polymer
MX9603560A (es) Composiciones de prostaglandinas estables en almacenamiento.
DK0771330T3 (da) Modificering af (co)polymerer med cykliske ketonperoxider
FI960546A0 (fi) Polymeerin stabilointi stabiililla vapaalla radikaalilla
ES2128469T3 (es) Polimeros de funcionalidad carbamato curables.
CA2214674A1 (en) Cyclic ketone peroxides as polymerization initiators
EP0322182A3 (de) Azabicyclische-Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
MXPA02012937A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas.
DE69318636D1 (de) Substituierte Aminothienopyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE80314T1 (de) Zusammensetzung zur herstellung von antithrombotischen medizinischen erzeugnissen.
PT1204659E (pt) Benzofuranos serotoninergicos
CA2080820A1 (fr) Derives azoiques, compositions pharmaceutiques et desinfectantes les contenant et leurs utilisations
CA2061995A1 (en) Use of oxime ether derivatives for bioregulation in plants
TW349104B (en) A base resin for use in chemically amplified resist and a manufacturing method thereof the invention relates to a base resin for use in a chemically amplified resist and a manufacturing method thereof, the base resin containing two t-butyl groups
DE69322235D1 (de) Thiomarinol-Derivate und Verfahren zu ihrer Herstellung
MY115690A (en) Cyclic ketone peroxide formulations
ES2067552T3 (es) Estratificados de espuma rigida de poliuretano de celdillas cerradas.
AR000079A1 (es) Composíción de peróxido transportable estable durante el almacenamiento, y uso de la composición.
ES2155476T3 (es) Aril-tio-alquil-tio-piridinas sustituidas.
FI963055A0 (fi) Kondensaatio- ja additiopolymeereja, jotka sisältävät N,N'-sillan sisältäviä bis(tetrametyylipiperidinyylioksi)-ryhmiä
UA33144A (uk) Гумова суміш на основі високомолекулярного метилвінілсилоксанового каучуку
ES2069465A1 (es) Nuevos cooligomeros de piperidin-triazina para utilizar como estabilizadores para materiales organicos.
DE69633034D1 (de) Verfahren zur Herstellung von Bitumen-Polymerzusammensetzungen
TW327182B (en) Burning resistant phosphide with double functional groups

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee